Search for: "Novartis Pharmaceuticals Corporation"
Results 121 - 140
of 219
Sorted by Relevance
|
Sort by Date
18 Nov 2009, 4:57 am
Teva Pharmaceuticals USA Inc. et al. [read post]
18 Nov 2009, 4:57 am
Teva Pharmaceuticals USA Inc. et al. [read post]
9 Jan 2012, 4:00 am
Novartis Pharmaceuticals Corporation, Case No. 2:08-CV-02088 (W.D. [read post]
6 Dec 2013, 3:14 pm
Switzerland also has a long history of social equality, and many citizens were offended by cases like that of Daniel Vasella, the former chief executive of the pharmaceutical company Novartis, who this year demanded a $78 million severance package in return for a promise not to share his know-how with any competitors. [read post]
22 Jun 2012, 11:29 am
Berk wrote the following in his blog, The Corporate Observer. [read post]
27 Jul 2011, 1:01 am
Highlights this week included: Corporate self-interest and strategic choices: Gilead licenses to Medicines Patent Pool (IP Watch) (KEI) Glybera (Alipogene tiparvovec) – EU: EMA continues to defer approval of first gene therapy application in Europe (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of equivalents: Duramed Pharmaceuticals, Inc. v. [read post]
19 May 2011, 1:15 pm
Novartis Pharmaceuticals Corp., ___ F. [read post]
29 Oct 2010, 4:32 pm
9/1/2010 - Off-label marketing practices involving Botox AstraZeneca - $520 M- 4/27/2010 - Illegal marketing - anti-psychotic drug Seroquel Novartis Pharmaceuticals $422.5 million ($237.5 M - Civil allegations and a $185 M criminal fine) 9/30/2010 Unapproved promotion of Trileptal Forest Laboratories - $313 M - ($149M -Civil claims, a $150M criminal fine, and $14 M… [read post]
19 Jul 2010, 7:07 pm
The latest example is Novartis, a pharmaceutical company, which settled a gender discrimination class action for up to $175 million last week. [read post]
27 Mar 2012, 12:58 pm
Novartis Pharmaceutical Corp., 2012 U.S. [read post]
18 Apr 2014, 11:00 am
Novartis Pharmaceuticals Corp., No. 13-15433, 2014 U.S. [read post]
11 Jul 2011, 4:47 pm
Kudos to The RPM Report team, which took note of some statements made during a recent meeting of FDA’s Arthritis Drugs Advisory Committee to discuss Novartis Pharmaceuticals Corporation’s (“Novartis’”) supplemental Biologics License Application (“sBLA”) for ILARIS (canakinumab) for the treatment of gouty arthritis attacks in certain patients. [read post]
26 Oct 2007, 2:03 am
Court of Appeal (Civil Division) Neil Martin Ltd v HM Revenue & Customs [2007] EWCA Civ 1041 (25 October 2007) Cadogan & Anor v Sportelli & Anor [2007] EWCA Civ 1042 (25 October 2007) Boudh v Bodh [2007] EWCA Civ 1019 (25 October 2007) AA (Somalia) v SSHD [2007] EWCA Civ 1040 (25 October 2007) Kohn v Wagschal & Ors [2007] EWCA Civ 1022 (24 October 2007) Poole & Ors v HM Treasury [2007] EWCA Civ 1021 (24 October 2007) Wright & Ors, R (on the… [read post]
24 Jan 2020, 10:24 am
Also tagged in this scheme were Novartis, Dendreon, Onyx, Questcor, and Bayer. [read post]
27 Aug 2011, 7:55 pm
This is "the sport of kings," that only large corporations can play. [read post]
2 Dec 2009, 4:31 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: World AIDS Day: Make it happen (Patent Baristas) (IP Watch) Venezuela to examine all pharmaceutical patents (IP tango) General World AIDS Day: Make it happen (Patent Baristas) (IP Watch) Biodiversity negotiations need to allow for flexibility in business, industry says (IP Watch) Brazilian government tailors a bill… [read post]
30 Apr 2014, 4:30 am
Novartis Pharmaceuticals Corp., 2014 U.S. [read post]
15 Feb 2013, 12:10 pm
Novartis Pharmaceuticals Corp., ___ Fed. [read post]
12 Mar 2012, 5:41 pm
Novartis Pharmaceuticals Corp., No. 33-av-00001 (D.N.J., Mar. 7, 2012) (Complaint) Plumbers and Pipefitters Local 572 Health and Welfare Fund v. [read post]
25 Apr 2013, 4:24 am
Sodexo tops the list for 2013, followed by PricewaterhouseCoopers, Kaiser Permanente, Ernst & Young, MasterCard Worldwide, Novartis Pharmaceuticals Corporation, Procter & Gamble, Prudential Financial, Accenture and Johnson & Johnson. [read post]